CA2055041A1 - Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses - Google Patents

Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses

Info

Publication number
CA2055041A1
CA2055041A1 CA002055041A CA2055041A CA2055041A1 CA 2055041 A1 CA2055041 A1 CA 2055041A1 CA 002055041 A CA002055041 A CA 002055041A CA 2055041 A CA2055041 A CA 2055041A CA 2055041 A1 CA2055041 A1 CA 2055041A1
Authority
CA
Canada
Prior art keywords
formula
group
hiv
compound
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002055041A
Other languages
English (en)
French (fr)
Inventor
Bruce J. Dezube
Arthur B. Pardee
Ruth M. Ruprecht
William J. Novick, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2055041A1 publication Critical patent/CA2055041A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002055041A 1990-11-07 1991-11-06 Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses Abandoned CA2055041A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61023090A 1990-11-07 1990-11-07
US610,230 1990-11-07

Publications (1)

Publication Number Publication Date
CA2055041A1 true CA2055041A1 (en) 1992-05-08

Family

ID=24444220

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002055041A Abandoned CA2055041A1 (en) 1990-11-07 1991-11-06 Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses

Country Status (16)

Country Link
EP (1) EP0484785B1 (enExample)
JP (1) JPH054922A (enExample)
KR (1) KR920009397A (enExample)
AT (1) ATE138266T1 (enExample)
AU (1) AU649278B2 (enExample)
CA (1) CA2055041A1 (enExample)
DE (1) DE69119700T2 (enExample)
DK (1) DK0484785T3 (enExample)
ES (1) ES2087205T3 (enExample)
GR (1) GR3020017T3 (enExample)
HU (1) HUT61468A (enExample)
IE (1) IE913879A1 (enExample)
IL (1) IL99966A0 (enExample)
PT (1) PT99434A (enExample)
TW (1) TW209169B (enExample)
ZA (1) ZA918801B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59304710D1 (de) * 1992-02-22 1997-01-23 Hoechst Ag Verwendung von Xanthinderivaten zur Behandlung von Muskelschädigungen nach vollständiger Unterbrechung der Blutzirkulation
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
ES2275400B1 (es) * 2005-04-20 2008-04-01 Universidad Autonoma De Madrid Uso de compuestos agonistas de la actividad tubulina desacetilasa de la proteina hdac6 en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y sus aplicaciones en el tratamiento de infecciones virales.
WO2009108383A2 (en) 2008-02-29 2009-09-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2011028835A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2611807A2 (en) 2010-09-01 2013-07-10 Concert Pharmaceuticals Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
MX2014012384A (es) 2012-04-13 2014-11-26 Concert Pharmaceuticals Inc Derivados sustituidos de xantina.
WO2013159006A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
CH608236A5 (enExample) * 1974-01-22 1978-12-29 Wuelfing J A Fa
US4663317A (en) * 1984-04-18 1987-05-05 Board Of Regents, University Of Texas System Methods and compositions for treating viral infections
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
GB8610136D0 (en) * 1986-04-25 1986-05-29 Wellcome Found Compounds
DE3725554A1 (de) * 1987-08-01 1989-02-09 Hoechst Ag Pharmazeutisches kombinationspraeparat sowie dessen herstellung und verwendung

Also Published As

Publication number Publication date
DE69119700T2 (de) 1996-11-07
IE913879A1 (en) 1992-05-20
TW209169B (enExample) 1993-07-11
ZA918801B (en) 1992-12-30
HUT61468A (en) 1993-01-28
AU8699891A (en) 1992-05-14
AU649278B2 (en) 1994-05-19
JPH054922A (ja) 1993-01-14
EP0484785B1 (en) 1996-05-22
DE69119700D1 (de) 1996-06-27
ES2087205T3 (es) 1996-07-16
ATE138266T1 (de) 1996-06-15
EP0484785A2 (en) 1992-05-13
EP0484785A3 (en) 1992-12-16
GR3020017T3 (en) 1996-08-31
KR920009397A (ko) 1992-06-25
PT99434A (pt) 1992-09-30
IL99966A0 (en) 1992-08-18
HU913502D0 (en) 1992-01-28
DK0484785T3 (da) 1996-09-23

Similar Documents

Publication Publication Date Title
Balzarini et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl) adenine, a selective anti-human immunodeficiency virus agent.
Easmon et al. Pyridazines. 63. Novel thiosemicarbazones derived from formyl-and acyldiazines: synthesis, effects on cell proliferation, and synergism with antiviral agents
CA2055041A1 (en) Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses
JPH06507902A (ja) 肝臓で代謝される薬物前駆物の決定とその治療的利用
US20010009914A1 (en) Acridone-derived compounds useful as antineoplastic and antiretroviral agents
Balzarini et al. Anti‐retrovirus activity of 9‐(2‐phosphonylmethoxyethyl) adenine (PMEA) in vivo increases when it is less frequently administered
US6172116B1 (en) Use of aminoadamantane compounds as immunoregulators
CA2155323C (en) Novel use as anti-inflammatory agents for bis-heterocyclic compounds and pharmaceutical compositions thereof
EP0610519B1 (en) Anti-hiv drug
EP0476066A1 (en) ANTIVIRAL COMPOSITIONS CONTAINING 3'-AZIDO-2 ', 3'-DIDEOXY-5-METHYLCYTIDINE.
US6979687B1 (en) Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities
IE914162A1 (en) Use of xanthines for the preparation of a medicament¹effective for inhibiting the effects of allograft reaction¹in humans
US20050209243A1 (en) Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities
CA2014663A1 (en) Use of dipyrido (4,3-b) (3,4-f) indoles for the preparation of drugs useful in the treatment of aids
HUP0303818A2 (hu) HIV reverz transzkriptáz inhibitorként alkalmazható triciklikus vegyületek és ezeket tartalmazó gyógyszerkészítmények
US5962480A (en) Drug for ameliorating brain diseases
JP2003510362A (ja) 細胞内原核生物、ｄｎａウイルス及びレトロウイルスによる感染を治療するための、３−ヒドロキシ−４−ピロンのガリウム錯体
JP2005508283A (ja) 抗ｔｂ活性を有する新規ファーマコフォアとしてのピラノクマリン化合物
EP0914824A1 (en) Preventive and remedy for viral infections
WO1991018604A1 (fr) Utilisation de derives de la tetrahydro isoquinoleine pour la preparation de medicaments anti-tumoraux
MXPA06011823A (es) Terapia de combinacion, que comprende un antagonista del receptor de la adenosina a1 y un inhibidor de la aldosterona.
US5541212A (en) Use of cimetidine for the control of retrovirus infections
US20100093655A1 (en) Use of riluzole and derivatives thereof for producing new drugs
US20120022088A1 (en) Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer
EP3022203A1 (en) Novel ureido derivatives of naphthalenesulfonic acids

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued